Ciphergen’s rollercoaster revenue growth over the last few quarters — culminating in a hefty shortfall of expectations in the quarter that ended June 30 — has made investors wary, and its stock has tumbled to about half its value since the beginning of July. Meanwhile, the company has been pointing to a possible future upturn driven by new products and diagnostic tests, and has promised to rein in costs by making cuts in its instrumentation division.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.